| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| MicroRNAs | 17 | 2024 | 838 | 4.560 |
Why?
|
| Laryngeal Neoplasms | 6 | 2016 | 83 | 2.730 |
Why?
|
| Biomarkers, Tumor | 12 | 2025 | 1492 | 2.710 |
Why?
|
| Prostatic Neoplasms | 19 | 2020 | 1546 | 2.410 |
Why?
|
| Neoplastic Stem Cells | 6 | 2016 | 291 | 1.820 |
Why?
|
| Carcinoma, Squamous Cell | 5 | 2015 | 673 | 1.650 |
Why?
|
| Neoplasm Recurrence, Local | 6 | 2020 | 1143 | 1.260 |
Why?
|
| Gene Expression Regulation, Neoplastic | 15 | 2017 | 1892 | 1.190 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2025 | 43 | 0.920 |
Why?
|
| RNA, Untranslated | 1 | 2025 | 113 | 0.910 |
Why?
|
| Gene Expression Profiling | 11 | 2024 | 1708 | 0.900 |
Why?
|
| Chordoma | 3 | 2013 | 20 | 0.890 |
Why?
|
| ATP-Binding Cassette Transporters | 2 | 2015 | 190 | 0.890 |
Why?
|
| Mutation | 6 | 2019 | 5845 | 0.870 |
Why?
|
| Alternative Splicing | 2 | 2019 | 351 | 0.740 |
Why?
|
| Mutation, Missense | 3 | 2015 | 874 | 0.720 |
Why?
|
| SOXB1 Transcription Factors | 3 | 2015 | 57 | 0.710 |
Why?
|
| Transfection | 6 | 2015 | 1069 | 0.680 |
Why?
|
| rab3 GTP-Binding Proteins | 1 | 2019 | 7 | 0.630 |
Why?
|
| Optic Atrophy | 1 | 2019 | 47 | 0.610 |
Why?
|
| Abnormalities, Multiple | 4 | 2019 | 958 | 0.580 |
Why?
|
| Skin Abnormalities | 2 | 2014 | 33 | 0.560 |
Why?
|
| Microcephaly | 3 | 2019 | 330 | 0.550 |
Why?
|
| Male | 39 | 2024 | 61317 | 0.520 |
Why?
|
| Cataract | 1 | 2019 | 224 | 0.520 |
Why?
|
| Receptors, Fibroblast Growth Factor | 4 | 2004 | 58 | 0.520 |
Why?
|
| CHARGE Syndrome | 1 | 2015 | 8 | 0.500 |
Why?
|
| Neoplasms | 2 | 2025 | 2780 | 0.500 |
Why?
|
| Prostate | 3 | 2017 | 434 | 0.500 |
Why?
|
| Up-Regulation | 6 | 2015 | 867 | 0.500 |
Why?
|
| Tongue Neoplasms | 1 | 2015 | 19 | 0.500 |
Why?
|
| Centrioles | 1 | 2015 | 13 | 0.490 |
Why?
|
| RNA Splice Sites | 1 | 2015 | 88 | 0.490 |
Why?
|
| Cell Proliferation | 5 | 2015 | 2303 | 0.480 |
Why?
|
| White Coat Hypertension | 1 | 2015 | 10 | 0.480 |
Why?
|
| Usher Syndromes | 1 | 2015 | 10 | 0.480 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 7 | 2018 | 1016 | 0.480 |
Why?
|
| Saliva | 1 | 2015 | 114 | 0.480 |
Why?
|
| Hypogonadism | 1 | 2019 | 284 | 0.480 |
Why?
|
| Down-Regulation | 6 | 2015 | 701 | 0.470 |
Why?
|
| alpha-Crystallin B Chain | 1 | 2014 | 2 | 0.460 |
Why?
|
| Dwarfism | 1 | 2015 | 98 | 0.460 |
Why?
|
| Humans | 49 | 2025 | 124705 | 0.450 |
Why?
|
| Prognosis | 6 | 2025 | 4620 | 0.450 |
Why?
|
| DNA Helicases | 1 | 2015 | 231 | 0.450 |
Why?
|
| Ephrin-B1 | 1 | 2013 | 8 | 0.430 |
Why?
|
| Cornea | 1 | 2019 | 652 | 0.430 |
Why?
|
| Middle Aged | 16 | 2024 | 26884 | 0.430 |
Why?
|
| Foot Deformities | 1 | 2013 | 4 | 0.430 |
Why?
|
| Real-Time Polymerase Chain Reaction | 5 | 2020 | 503 | 0.430 |
Why?
|
| Tyrosinemias | 1 | 2013 | 5 | 0.430 |
Why?
|
| Skull Base Neoplasms | 1 | 2013 | 35 | 0.410 |
Why?
|
| ZAP-70 Protein-Tyrosine Kinase | 1 | 2012 | 13 | 0.410 |
Why?
|
| Tumor Cells, Cultured | 6 | 2016 | 1062 | 0.410 |
Why?
|
| Neutropenia | 1 | 2014 | 197 | 0.400 |
Why?
|
| Cochlea | 1 | 2013 | 85 | 0.400 |
Why?
|
| Lymph Nodes | 1 | 2014 | 380 | 0.390 |
Why?
|
| Case-Control Studies | 6 | 2024 | 3293 | 0.380 |
Why?
|
| Severe Combined Immunodeficiency | 1 | 2012 | 106 | 0.380 |
Why?
|
| Limb Deformities, Congenital | 1 | 2013 | 106 | 0.380 |
Why?
|
| Intellectual Disability | 1 | 2019 | 1056 | 0.370 |
Why?
|
| Craniofacial Abnormalities | 1 | 2013 | 240 | 0.370 |
Why?
|
| Lymphocytes | 1 | 2013 | 410 | 0.370 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2013 | 142 | 0.360 |
Why?
|
| Neoplasm Proteins | 2 | 2014 | 670 | 0.350 |
Why?
|
| Proteins | 1 | 2015 | 1036 | 0.330 |
Why?
|
| Female | 24 | 2024 | 66577 | 0.330 |
Why?
|
| Head and Neck Neoplasms | 1 | 2014 | 504 | 0.320 |
Why?
|
| Pedigree | 4 | 2019 | 1604 | 0.320 |
Why?
|
| Sequence Analysis, DNA | 1 | 2015 | 1757 | 0.320 |
Why?
|
| Prostatectomy | 3 | 2020 | 344 | 0.300 |
Why?
|
| Prenatal Diagnosis | 1 | 2012 | 596 | 0.300 |
Why?
|
| DNA-Binding Proteins | 2 | 2015 | 2048 | 0.280 |
Why?
|
| Cell Line, Tumor | 7 | 2015 | 3344 | 0.270 |
Why?
|
| Fibroblast Growth Factor 2 | 2 | 2004 | 55 | 0.270 |
Why?
|
| Bone Neoplasms | 1 | 2011 | 420 | 0.270 |
Why?
|
| Cell Cycle Proteins | 2 | 2015 | 656 | 0.270 |
Why?
|
| Adult | 11 | 2024 | 29554 | 0.270 |
Why?
|
| Phenotype | 4 | 2019 | 4258 | 0.260 |
Why?
|
| Turkey | 2 | 2019 | 64 | 0.260 |
Why?
|
| Genes, Dominant | 2 | 2004 | 245 | 0.250 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2015 | 1291 | 0.250 |
Why?
|
| AC133 Antigen | 2 | 2016 | 35 | 0.250 |
Why?
|
| cdc25 Phosphatases | 1 | 2005 | 21 | 0.250 |
Why?
|
| Genetic Therapy | 2 | 2014 | 687 | 0.240 |
Why?
|
| Liquid Biopsy | 1 | 2025 | 14 | 0.240 |
Why?
|
| Aged | 8 | 2015 | 19830 | 0.240 |
Why?
|
| Apoptosis | 5 | 2015 | 1802 | 0.230 |
Why?
|
| Adenoviridae | 2 | 2004 | 606 | 0.220 |
Why?
|
| Electroconvulsive Therapy | 1 | 2024 | 68 | 0.210 |
Why?
|
| ROC Curve | 2 | 2015 | 568 | 0.210 |
Why?
|
| Antineoplastic Agents | 2 | 2011 | 1695 | 0.200 |
Why?
|
| RNA, Long Noncoding | 1 | 2025 | 213 | 0.200 |
Why?
|
| Blotting, Western | 3 | 2015 | 1103 | 0.190 |
Why?
|
| Schizophrenia | 1 | 2024 | 311 | 0.180 |
Why?
|
| Tissue Kallikreins | 1 | 2020 | 7 | 0.180 |
Why?
|
| Disease Progression | 3 | 2015 | 2057 | 0.160 |
Why?
|
| Infant | 7 | 2016 | 12384 | 0.160 |
Why?
|
| INDEL Mutation | 1 | 2019 | 87 | 0.150 |
Why?
|
| RNA, Neoplasm | 1 | 2018 | 137 | 0.150 |
Why?
|
| Siblings | 1 | 2019 | 197 | 0.140 |
Why?
|
| Child | 7 | 2019 | 24173 | 0.140 |
Why?
|
| Child, Preschool | 6 | 2016 | 13882 | 0.140 |
Why?
|
| Homozygote | 1 | 2019 | 547 | 0.140 |
Why?
|
| Receptors, Oxytocin | 1 | 2016 | 19 | 0.130 |
Why?
|
| Melanoma | 1 | 2004 | 941 | 0.130 |
Why?
|
| Skin Neoplasms | 1 | 2004 | 872 | 0.130 |
Why?
|
| Flow Cytometry | 2 | 2013 | 802 | 0.130 |
Why?
|
| Mannose-Binding Protein-Associated Serine Proteases | 1 | 2015 | 1 | 0.130 |
Why?
|
| Phorbols | 1 | 2015 | 5 | 0.120 |
Why?
|
| Aldehyde Dehydrogenase | 1 | 2015 | 40 | 0.120 |
Why?
|
| Spheroids, Cellular | 1 | 2015 | 57 | 0.120 |
Why?
|
| Mendelian Randomization Analysis | 1 | 2015 | 84 | 0.120 |
Why?
|
| Cell Survival | 4 | 2012 | 812 | 0.120 |
Why?
|
| Hep G2 Cells | 1 | 2015 | 85 | 0.120 |
Why?
|
| G1 Phase | 1 | 2015 | 67 | 0.120 |
Why?
|
| Preoperative Period | 1 | 2015 | 88 | 0.120 |
Why?
|
| RNA Interference | 1 | 2016 | 500 | 0.120 |
Why?
|
| Cell Differentiation | 4 | 2011 | 1896 | 0.110 |
Why?
|
| Cell Division | 4 | 2004 | 781 | 0.110 |
Why?
|
| Gold | 1 | 2014 | 48 | 0.110 |
Why?
|
| Octamer Transcription Factor-3 | 1 | 2014 | 41 | 0.110 |
Why?
|
| Microarray Analysis | 1 | 2015 | 229 | 0.110 |
Why?
|
| Promoter Regions, Genetic | 2 | 2016 | 1330 | 0.110 |
Why?
|
| Metal Nanoparticles | 1 | 2014 | 41 | 0.110 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2015 | 216 | 0.110 |
Why?
|
| Cell Movement | 2 | 2015 | 846 | 0.110 |
Why?
|
| Retinitis Pigmentosa | 1 | 2015 | 84 | 0.110 |
Why?
|
| Phosphotransferases | 1 | 2014 | 40 | 0.110 |
Why?
|
| MCF-7 Cells | 1 | 2014 | 222 | 0.110 |
Why?
|
| Postoperative Period | 1 | 2015 | 333 | 0.110 |
Why?
|
| Cytoskeletal Proteins | 1 | 2015 | 270 | 0.110 |
Why?
|
| HeLa Cells | 1 | 2015 | 806 | 0.110 |
Why?
|
| Hyaluronan Receptors | 1 | 2014 | 66 | 0.110 |
Why?
|
| RNA, Transfer | 1 | 2014 | 72 | 0.110 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2014 | 108 | 0.110 |
Why?
|
| Fibroblasts | 2 | 2015 | 885 | 0.110 |
Why?
|
| Immunohistochemistry | 3 | 2014 | 1694 | 0.110 |
Why?
|
| Prostatic Hyperplasia | 1 | 2014 | 117 | 0.110 |
Why?
|
| Hearing Loss | 1 | 2015 | 135 | 0.110 |
Why?
|
| Biopsy, Needle | 1 | 2014 | 231 | 0.110 |
Why?
|
| Aged, 80 and over | 2 | 2015 | 6584 | 0.110 |
Why?
|
| Area Under Curve | 1 | 2014 | 314 | 0.110 |
Why?
|
| DNA Mutational Analysis | 1 | 2015 | 794 | 0.110 |
Why?
|
| Oncogenes | 1 | 2014 | 167 | 0.110 |
Why?
|
| Central Nervous System Diseases | 1 | 2014 | 107 | 0.110 |
Why?
|
| Cutis Laxa | 1 | 2013 | 11 | 0.110 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2014 | 204 | 0.100 |
Why?
|
| RNA, Messenger | 2 | 2013 | 2821 | 0.100 |
Why?
|
| Cell Separation | 1 | 2014 | 229 | 0.100 |
Why?
|
| Gene Regulatory Networks | 1 | 2015 | 351 | 0.100 |
Why?
|
| Lymphatic Metastasis | 1 | 2014 | 419 | 0.100 |
Why?
|
| Prostate-Specific Antigen | 1 | 2014 | 255 | 0.100 |
Why?
|
| Karyotype | 1 | 2013 | 28 | 0.100 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2014 | 124 | 0.100 |
Why?
|
| CDC2 Protein Kinase | 2 | 2004 | 34 | 0.100 |
Why?
|
| Exons | 1 | 2015 | 797 | 0.100 |
Why?
|
| Heterozygote | 1 | 2015 | 671 | 0.100 |
Why?
|
| Hashimoto Disease | 1 | 2013 | 21 | 0.100 |
Why?
|
| Ichthyosis | 1 | 2012 | 29 | 0.100 |
Why?
|
| Dermatitis | 1 | 2012 | 26 | 0.100 |
Why?
|
| Neoplasm Staging | 2 | 2014 | 1278 | 0.100 |
Why?
|
| Lymphocyte Count | 1 | 2012 | 118 | 0.100 |
Why?
|
| Hamartoma | 1 | 2013 | 52 | 0.100 |
Why?
|
| Signal Transduction | 4 | 2006 | 4534 | 0.100 |
Why?
|
| Neoplasm Invasiveness | 1 | 2014 | 620 | 0.100 |
Why?
|
| Chromosome Aberrations | 1 | 2015 | 612 | 0.100 |
Why?
|
| Skin | 1 | 2015 | 519 | 0.100 |
Why?
|
| Stem Cells | 2 | 2007 | 706 | 0.100 |
Why?
|
| Disease-Free Survival | 1 | 2014 | 898 | 0.100 |
Why?
|
| Cluster Analysis | 1 | 2013 | 397 | 0.100 |
Why?
|
| Nanoparticles | 1 | 2014 | 232 | 0.100 |
Why?
|
| Cohort Studies | 2 | 2018 | 4799 | 0.100 |
Why?
|
| Immunoglobulin E | 1 | 2012 | 160 | 0.100 |
Why?
|
| Antigens, CD | 1 | 2014 | 431 | 0.090 |
Why?
|
| Imatinib Mesylate | 1 | 2011 | 45 | 0.090 |
Why?
|
| Nervous System Diseases | 1 | 2015 | 375 | 0.090 |
Why?
|
| Neoplasm Metastasis | 1 | 2014 | 686 | 0.090 |
Why?
|
| Vidarabine | 1 | 2011 | 79 | 0.090 |
Why?
|
| Glycoproteins | 1 | 2014 | 370 | 0.090 |
Why?
|
| Etoposide | 1 | 2011 | 114 | 0.090 |
Why?
|
| Pilot Projects | 1 | 2015 | 1396 | 0.090 |
Why?
|
| Polymerase Chain Reaction | 1 | 2015 | 1578 | 0.090 |
Why?
|
| Amino Acid Substitution | 1 | 2012 | 398 | 0.090 |
Why?
|
| Spinal Cord Neoplasms | 1 | 2012 | 71 | 0.090 |
Why?
|
| Amino Acid Sequence | 1 | 2015 | 2717 | 0.090 |
Why?
|
| Base Sequence | 1 | 2015 | 3101 | 0.090 |
Why?
|
| Benzamides | 1 | 2011 | 108 | 0.090 |
Why?
|
| Autism Spectrum Disorder | 1 | 2016 | 390 | 0.090 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2011 | 99 | 0.090 |
Why?
|
| Vincristine | 1 | 2011 | 191 | 0.090 |
Why?
|
| Rare Diseases | 1 | 2013 | 191 | 0.090 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2012 | 218 | 0.090 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2011 | 127 | 0.090 |
Why?
|
| Survival Analysis | 1 | 2014 | 1504 | 0.090 |
Why?
|
| Recurrence | 1 | 2014 | 1415 | 0.090 |
Why?
|
| Early Detection of Cancer | 1 | 2014 | 360 | 0.090 |
Why?
|
| Exome | 1 | 2015 | 1033 | 0.090 |
Why?
|
| Molecular Sequence Data | 1 | 2015 | 3891 | 0.090 |
Why?
|
| Peptides | 1 | 2014 | 810 | 0.090 |
Why?
|
| Killer Cells, Natural | 1 | 2012 | 330 | 0.090 |
Why?
|
| Doxorubicin | 1 | 2011 | 290 | 0.080 |
Why?
|
| Cisplatin | 1 | 2011 | 249 | 0.080 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2012 | 397 | 0.080 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2011 | 184 | 0.080 |
Why?
|
| DNA Methylation | 1 | 2016 | 1008 | 0.080 |
Why?
|
| Cell Lineage | 1 | 2011 | 343 | 0.080 |
Why?
|
| Piperazines | 1 | 2011 | 239 | 0.080 |
Why?
|
| Family | 1 | 2012 | 564 | 0.080 |
Why?
|
| Cells, Cultured | 1 | 2015 | 3055 | 0.080 |
Why?
|
| Methotrexate | 1 | 2011 | 337 | 0.080 |
Why?
|
| Epigenesis, Genetic | 1 | 2014 | 678 | 0.080 |
Why?
|
| Genetic Variation | 1 | 2015 | 1498 | 0.080 |
Why?
|
| Ki-67 Antigen | 2 | 2006 | 113 | 0.080 |
Why?
|
| Diagnosis, Differential | 1 | 2014 | 1873 | 0.080 |
Why?
|
| Pyrimidines | 1 | 2011 | 371 | 0.080 |
Why?
|
| Genotype | 1 | 2014 | 2558 | 0.070 |
Why?
|
| Computational Biology | 1 | 2013 | 810 | 0.070 |
Why?
|
| Nuclear Proteins | 1 | 2014 | 1266 | 0.070 |
Why?
|
| Genome-Wide Association Study | 1 | 2015 | 1686 | 0.070 |
Why?
|
| Microspheres | 1 | 2007 | 70 | 0.070 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2014 | 2634 | 0.070 |
Why?
|
| Cartilage | 1 | 2007 | 49 | 0.070 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2011 | 725 | 0.070 |
Why?
|
| Adipocytes, Brown | 1 | 2007 | 25 | 0.070 |
Why?
|
| Chondrogenesis | 1 | 2007 | 26 | 0.070 |
Why?
|
| Somatomedins | 1 | 2006 | 37 | 0.070 |
Why?
|
| Chondrocytes | 1 | 2007 | 50 | 0.070 |
Why?
|
| Time Factors | 4 | 2006 | 6323 | 0.070 |
Why?
|
| Ossification, Heterotopic | 1 | 2007 | 41 | 0.070 |
Why?
|
| Neurites | 1 | 2006 | 42 | 0.070 |
Why?
|
| Ganglia, Spinal | 1 | 2006 | 69 | 0.070 |
Why?
|
| Gene Expression Regulation | 2 | 2013 | 2524 | 0.070 |
Why?
|
| Transcription Factor AP-1 | 1 | 2006 | 109 | 0.070 |
Why?
|
| Osteogenesis | 1 | 2007 | 154 | 0.060 |
Why?
|
| Histone Acetyltransferases | 1 | 2006 | 314 | 0.060 |
Why?
|
| Infant, Newborn | 2 | 2015 | 8163 | 0.060 |
Why?
|
| Monocytes | 1 | 2007 | 353 | 0.060 |
Why?
|
| Trans-Activators | 2 | 2006 | 799 | 0.060 |
Why?
|
| Isoenzymes | 1 | 2005 | 228 | 0.060 |
Why?
|
| Breast Neoplasms | 2 | 2014 | 2509 | 0.060 |
Why?
|
| G2 Phase | 1 | 2004 | 44 | 0.060 |
Why?
|
| Transcription Factors | 1 | 2014 | 2594 | 0.060 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2004 | 81 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2006 | 488 | 0.050 |
Why?
|
| Brain | 1 | 2015 | 2996 | 0.050 |
Why?
|
| Oxygen | 1 | 2007 | 555 | 0.050 |
Why?
|
| Sialoglycoproteins | 1 | 2003 | 48 | 0.050 |
Why?
|
| Fibroblast Growth Factors | 1 | 2004 | 154 | 0.050 |
Why?
|
| Cyclins | 1 | 2004 | 101 | 0.050 |
Why?
|
| Animals | 8 | 2014 | 34235 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2003 | 89 | 0.050 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2003 | 127 | 0.050 |
Why?
|
| Cytogenetics | 1 | 2001 | 16 | 0.050 |
Why?
|
| Cyclin B1 | 1 | 2001 | 8 | 0.050 |
Why?
|
| Precipitin Tests | 1 | 2001 | 155 | 0.050 |
Why?
|
| Cyclin B | 1 | 2001 | 22 | 0.050 |
Why?
|
| Lac Operon | 1 | 2001 | 96 | 0.050 |
Why?
|
| Chromosomes | 1 | 2001 | 199 | 0.050 |
Why?
|
| Cell Death | 1 | 2001 | 242 | 0.040 |
Why?
|
| Muscle, Skeletal | 1 | 2007 | 947 | 0.040 |
Why?
|
| Pregnancy | 1 | 2012 | 7171 | 0.040 |
Why?
|
| DNA, Neoplasm | 1 | 2020 | 303 | 0.040 |
Why?
|
| Interleukin-6 | 1 | 2001 | 418 | 0.040 |
Why?
|
| Cell Cycle | 1 | 2001 | 616 | 0.040 |
Why?
|
| Mice | 7 | 2014 | 17645 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2009 | 3154 | 0.040 |
Why?
|
| Mice, Inbred NOD | 2 | 2007 | 281 | 0.030 |
Why?
|
| Retrospective Studies | 1 | 2014 | 16263 | 0.030 |
Why?
|
| Adenocarcinoma | 1 | 2003 | 1023 | 0.030 |
Why?
|
| Mice, SCID | 2 | 2007 | 564 | 0.030 |
Why?
|
| Mice, Inbred CBA | 1 | 2014 | 31 | 0.030 |
Why?
|
| Cerebrum | 1 | 2014 | 33 | 0.030 |
Why?
|
| Endoribonucleases | 1 | 2014 | 84 | 0.030 |
Why?
|
| Hypertelorism | 1 | 2013 | 11 | 0.030 |
Why?
|
| Databases, Genetic | 1 | 2015 | 473 | 0.030 |
Why?
|
| Syndrome | 1 | 2015 | 1119 | 0.030 |
Why?
|
| Corpus Callosum | 1 | 2013 | 95 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 3 | 2007 | 4406 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2015 | 778 | 0.020 |
Why?
|
| Craniosynostoses | 1 | 2013 | 132 | 0.020 |
Why?
|
| RNA-Binding Proteins | 1 | 2014 | 573 | 0.020 |
Why?
|
| Young Adult | 2 | 2015 | 9023 | 0.020 |
Why?
|
| Phosphorylation | 2 | 2003 | 1631 | 0.020 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2012 | 618 | 0.020 |
Why?
|
| Stromal Cells | 1 | 2009 | 302 | 0.020 |
Why?
|
| 3T3 Cells | 1 | 2007 | 121 | 0.020 |
Why?
|
| Mice, Knockout | 2 | 2006 | 3742 | 0.020 |
Why?
|
| Gene Dosage | 1 | 2009 | 440 | 0.020 |
Why?
|
| Mucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 Protein | 1 | 2006 | 4 | 0.020 |
Why?
|
| Tumor Necrosis Factor Receptor-Associated Peptides and Proteins | 1 | 2006 | 13 | 0.020 |
Why?
|
| Hypoxanthine Phosphoribosyltransferase | 1 | 2006 | 35 | 0.020 |
Why?
|
| Myeloid Cells | 1 | 2007 | 100 | 0.020 |
Why?
|
| Cell Hypoxia | 1 | 2007 | 94 | 0.020 |
Why?
|
| Bone Morphogenetic Protein 2 | 1 | 2007 | 85 | 0.020 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2006 | 126 | 0.020 |
Why?
|
| Insulin Receptor Substrate Proteins | 1 | 2006 | 78 | 0.020 |
Why?
|
| Coculture Techniques | 1 | 2006 | 228 | 0.020 |
Why?
|
| Bone Morphogenetic Proteins | 1 | 2007 | 127 | 0.020 |
Why?
|
| Caspases | 1 | 2006 | 162 | 0.020 |
Why?
|
| Adolescent | 2 | 2015 | 19221 | 0.020 |
Why?
|
| Disease Models, Animal | 2 | 2007 | 4396 | 0.010 |
Why?
|
| Proteoglycans | 1 | 2004 | 88 | 0.010 |
Why?
|
| Phosphoproteins | 1 | 2006 | 418 | 0.010 |
Why?
|
| Nuclear Receptor Coactivator 3 | 1 | 2006 | 348 | 0.010 |
Why?
|
| Transforming Growth Factor beta | 1 | 2007 | 459 | 0.010 |
Why?
|
| Fibroblast Growth Factor 1 | 1 | 2003 | 14 | 0.010 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2006 | 558 | 0.010 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2003 | 35 | 0.010 |
Why?
|
| Osteopontin | 1 | 2003 | 48 | 0.010 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2003 | 66 | 0.010 |
Why?
|
| Neoplasm Transplantation | 1 | 2003 | 375 | 0.010 |
Why?
|
| Gene Silencing | 1 | 2003 | 236 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 2003 | 628 | 0.010 |
Why?
|
| Cell Line | 1 | 2007 | 2756 | 0.010 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2001 | 42 | 0.010 |
Why?
|
| Growth Substances | 1 | 2001 | 113 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2006 | 1701 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2003 | 410 | 0.010 |
Why?
|
| Pancreatic Neoplasms | 1 | 2006 | 691 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2006 | 2885 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2001 | 822 | 0.010 |
Why?
|
| STAT3 Transcription Factor | 1 | 2001 | 220 | 0.010 |
Why?
|
| Alleles | 1 | 2003 | 1615 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2001 | 1695 | 0.010 |
Why?
|
| Epithelial Cells | 1 | 2001 | 909 | 0.010 |
Why?
|